By The Life Science Report
Source: Streetwise Reports 09/13/2017
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm’s near-term clinical trial and catalysts.
A Sept. 11 research report revealed Quantum Genomics SA’s (ALQGC:PA; QNNTF:OTXQX) “Phase 2 study (NEW-HOPE, n=250) of brain aminopeptidase A inhibitor (BAPAI) candidate QGC001 has received regulatory clearance and is on track to initiate in Q4/17,” wrote analyst Jason McCarthy with Maxim Group. “BAPAIs are a new class of drug that targets the brain renin-angiotensin-aldosterone system (RAAS).”
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
Medical data suggest “20–25% of patients have poorly controlled blood pressure and are resistant to multiple drugs currently available; many of these patients have low renin-high vasopressin hypertension (LRHV),” indicated McCarthy.
Quantum’s BAPAI, QGC001, might help. “By targeting the brain RAAS versus the periphery, QGC001 can potentially control blood pressure in these patients,” the analyst explained, reiterating that “what makes BAPAIs unique is that they act centrally in the brain to regulate blood pressure in hypertensive patients and have no impact on healthy (normotensive) patients.”
As for the study design, NEW-HOPE “will enroll 250 hypertensive patients with at least 50% of patients being ethnic minorities (LRHV),” and treat them for eight weeks, explained McCarthy. Further, NEW-HOPE should “complete enrollment in Q4/18 and report data in mid-2019.”
Maxim expects catalysts “over the next year as Quantum continues to advance its BAPAI platform in hypertension and heart failure,” the analyst wrote.
One catalyst is the heart failure study (QGC101). “The n=75 study is ongoing at 15 centers” and “should be fully enrolled in Q4/17 with data expected in H1/18,” noted McCarthy.
A second catalyst is the anticipated initiation of “a combination study in hypertension evaluating a BAPAI plus a diuretic,” although the company hasn’t yet disclosed a start date, McCarthy said. “QGC001, in combination with currently approved therapies, could provide a more effective and more well-tolerated approach for treating high blood pressure and chronic heart failure.”
With respect to BAPAIs’ potential, McCarthy suggested, “Novel combination approaches that include BAPAIs could expand the hypertension and heart failure drug markets, in our view. The new European intellectual property covers the combination therapy of QGC001 with multiple medications that are widely prescribed to treat hypertension and heart failure.”
Maxim Group has a rating of Buy and a 12-month target price of €12 per share on Quantum Genomics, which is currently trading at about €3.10 per share.
Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you’ll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
( Companies Mentioned: ALQGC:PA; QNNTF:OTXQX,